Genome editing with Zinc Finger nucleases and TALENs has emerged as a promising technology for inducing localized sequence mutations in targeted genes. As CCR5 is the principal co-receptor for HIV, studies are underway to disrupt the gene in T cells and CD34+ Hematopoietic stem cells to protect the cells or their progeny from viral infection. So far, viral and plasmid vectors have been used for delivery of ZFNs/TALENs. However, this results in long-term expression of the nucleases, which may be potentially harmful, as increasing number of studies have documented dose-dependent toxicity of many engineered ZFN, presumably due to the generation of unintended double-stranded breaks at off-target sites. Transient expression of ZFNs/TALENs from mRNA may provide a feasible alternative as short term exposure to the nucleases is sufficient to cause permanent modification of the targeted gene. In this proposal, ZFN or TALEN expression from mRNA will be used as a strategy to disrupt CCR5 in CD34+ hematopoietic stem cells (HSCs). To overcome the hurdle of ZFN/TALEN mRNA delivery to CD34+ HSCs, which are difficult cells to transfect by conventional methods, we will develop lipid nanoparticles displaying a previously described DNA aptamer sgc8 that binds to Protein tyrosine kinase 7, expressed on the cells. Humanized BLT mice will be reconstituted with the ZFN/TALEN-modified CD34+ HSPCs and tested for protection from HIV challenge. Knowledge gained from the studies could lead to the development of a novel and safe approach to harness ZFN/TALEN for HIV gene therapy and even provide a potential method for direct delivery of the molecules to mobilized stem cells in vivo.

Public Health Relevance

Gene disruption by tailored Zinc Finger nuclease (ZFN) is an emerging technology with promising applications in gene therapy of various diseases including AIDS. The main goal of the proposed research is to use ZFN to disrupt the HIV co-receptor CCR5 in CD34+ hematopoietic stem cells as gene therapy to generate HIV resistant progeny. As long-term expression of ZFN can be harmful, we plan to develop a nanoparticle delivery platform for transient mRNA expression in the cells so that ZFNs/TALENs are expressed only for a short time to exert their CCR5 gene modification activity.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21HL116268-02
Application #
8517184
Study Section
Special Emphasis Panel (ZRG1-AARR-E (04))
Program Officer
Mitchell, Phyllis
Project Start
2012-08-01
Project End
2014-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
2
Fiscal Year
2013
Total Cost
$215,628
Indirect Cost
$72,828
Name
Texas Tech University
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
609980727
City
Lubbock
State
TX
Country
United States
Zip Code
79430
Manjunath, N; Yi, Guohua; Dang, Ying et al. (2013) Newer gene editing technologies toward HIV gene therapy. Viruses 5:2748-66